Full history for every metric is available with a Kvantra account
TCR2 Therapeutics Inc. (TCRR)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -153 | -166 | |||||
| Net profit | $m | -13 | -24 | -48 | -67 | -100 | -152 | -163 |
| EPS reported | $ | -3.93 | -4.20 | |||||
| Operating cashflow per share | $ | -2.63 | -2.63 | |||||
| Capex per share | $ | 0.40 | 0.40 | |||||
| FCF per share | $ | -3.03 | -3.03 | |||||
| Free cash flow | $m | -117 | -124 | |||||
| Net debt | $m | -95 | -110 | |||||
| Book value equity | $m | 141 | 101 | |||||
| Book value per share | $ | 3.65 | 2.58 | |||||
| Number of shares | m | 38.63 | 39.22 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.27 | 0.57 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -0.33 | -0.47 | |||||
| EV/EBITDA LTM | x | -0.67 | 0.55 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -393.51% | -265.56% | |||||
| FCF Yield | % | -303.03% | -213.35% | |||||
| Quality | ||||||||
| ROE | % | -107.78% | -71.90% | |||||
| ROIC | % | -78.87% | -78.87% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -2.17 | -20.74 | |||||
| Net Debt/EBITDA | x | -0.23 | -0.23 | |||||
| EBIT/Net interest | x | -2.61 | -2.61 | |||||
| Net debt/market cap | % | -247.31% | -189.84% | |||||
| Net debt/Equity | x | -0.68 | -1.09 | |||||
| Gross debt/equity | x | 0.38 | 0.06 | |||||
Company overview
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on developing cutting-edge T cell receptor (TCR) therapies for cancer patients. The company's lead investigational treatment, gavo-cel, is a unique mono TCR Fusion Construct T cell (TRuC-T cell) designed to target mesothelin-positive solid tumors. This therapy is currently being evaluated in Phase I/II clinical trials for non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Furthermore, TCR2 Therapeutics has concluded preclinical development for TC-510, another TRuC-T cell specifically engineered to target mesothelin on solid tumors. They are also advancing TC-520, a CD70-targeting TRuC-T cell designed with fratricide resistance for treating renal cell carcinoma. Founded in 2015, the company, formerly known as TCR2, Inc. until its name change in November 2016, is headquartered in Cambridge, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
TCR2 Therapeutics Inc. (TCRR)
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on developing cutting-edge T cell receptor (TCR) therapies for cancer patients. The company's lead investigational treatment, gavo-cel, is a unique mono TCR Fusion Construct T cell (TRuC-T cell) designed to target mesothelin-positive solid tumors. This therapy is currently being evaluated in Phase I/II clinical trials for non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Furthermore, TCR2 Therapeutics has concluded preclinical development for TC-510, another TRuC-T cell specifically engineered to target mesothelin on solid tumors. They are also advancing TC-520, a CD70-targeting TRuC-T cell designed with fratricide resistance for treating renal cell carcinoma. Founded in 2015, the company, formerly known as TCR2, Inc. until its name change in November 2016, is headquartered in Cambridge, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free